(Q40470679)

20 September 2017

1 reference

title

European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease. (English)

1 reference

20 September 2017

0 references

O'Brien SG

1

1 reference

20 September 2017

Kirkland MA

series ordinal

2

1 reference

20 September 2017

Goldman JM

series ordinal

3

1 reference

20 September 2017

publication date

1 January 1994

1 reference

European Journal of Cancer

20 September 2017

published in

1 reference

20 September 2017

volume

30A

1 reference

20 September 2017

issue

8

1 reference

20 September 2017

page(s)

1160-1164

1 reference

Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Triple helix-specific ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Antisense therapeutics in haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Antisense oligomers in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

BCR-ABL antisense purging in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

Antisense technology for cancer therapy: does it make sense?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2894%2990476-6

7 January 2021

10.1016/S0959-8049(94)90476-6

Identifiers

DOI

1 reference

20 September 2017

1 reference